Navigation Links
Abnormal overexpression of p53 is a predictive molecular biomarker

A common laboratory test that predicted poor outcome from traditional radiation and chemotherapy treatment for head and neck cancers now has been found to predict a good prognosis with treatment of p53 tumor suppressor gene therapy - making it potentially the first predictive biomarker test for a gene-based drug.

Researchers at Introgen Therapeutics, Inc., in Austin, Texas, found that patients with advanced squamous cell carcinoma of the head and neck cancer (SCCHN) whose pre-treatment tumor samples over-expressed p53 protein were significantly more likely to respond to Advexin therapy than those whose tumor showed little p53 protein. Advexin is a gene based drug, injected directly into tumors, which uses an adenoviral vector to deliver the wild type p53 gene to tumor cells.

Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

"Not only do we now have a way to predict if the gene therapy is likely to succeed, those patients for which it does work are the hardest patients to treat," said Laura L. Licato, Ph.D., associate director for Clinical Research at Introgen. "Accumulation of p53 has corresponded with a poor response to traditional therapies, as well as lower survival and a shorter time to disease progression."

"Selecting those who have the best chance of responding to p53 tumor suppressor gene therapy also helps perfect clinical trial testing," Licato said.

The researchers specifically found, in a subset of patients from phase II clinical trials, that 73 percent of patients with p53-positive tumors responded to the therapy, compared to a 14 percent response in patients with tumors that were p53-negative. Median survival also increased to 11 months for p53-positive patients, compared to 3 months for those with p53-negative tumors.

Head and neck cancer is the fifth most common cancer worldwide. Each year app roximately 40,000 Americans are diagnosed with head and neck cancer, and about 11,000 patients will die.

Many cancers have a dysfunction in the p53 pathway that regulates the cell cycle, helping to protect against cancer formation, but researchers estimate that more than 50 percent of head and neck tumors over-express p53 protein. That suggests a defect in protein regulation or that the p53 gene is mutated, incapable of producing effective protein. Tumors that are p53 negative likely have a working p53 gene and protein pathway, as normal p53 levels in cells are typically low.

Advexin is farthest along in federal Food and Drug Administration (FDA) review of any experimental gene therapy, according to Introgen, and has been granted fast track designation for an application of use in head and neck cancer. Results from two phase II clinical trials involving more than 160 SCCHN patients have found that 18 percent of patients treated with Advexin achieved local regional disease control. Two other phase III trials in the disease are underway. According to Introgen's published research, Advexin has also achieved 100 percent response when combined with chemotherapy to treat locally advanced breast cancer, and a 69 percent response when used with radiation to treat non-small cell lung cancer.


'"/>

Source:American Association for Cancer Research


Related biology news :

1. Protein overexpression at heart of heart failure
2. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
3. Source of molecular triggers in cutaneous T cell lymphoma identified
4. Plants, animals share molecular growth mechanisms
5. NYU researchers simulate molecular biological clock
6. Scientists reveal molecular secrets of the malaria parasite
7. Scientists identify molecular events that drive cell senescence
8. Researchers discover molecular mechanism that desensitizes us to cold
9. Findings have implications for tracking disease, drugs at the molecular level
10. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
11. At the molecular level, the predator is the prey
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOGĀ“s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... , ... April 25, 2017 , ... ... leading supplier of Common Lisp (CL) development tools, and market leader for ... includes key performance enhancements now available within the most effective system for developing ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert ... P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined ... 15, 2017. , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... denaturation in a cellular milieu; however, the broad application of this cellular target ... platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for ...
(Date:4/21/2017)... Austin, TX (PRWEB) , ... April 21, 2017 , ... ... more than a year, Formaspace is pleased to introduce it to top lab design ... Carolina. Formaspace CEO Jeff Turk and VP of Industrial Design and Engineering Greg Casey ...
Breaking Biology Technology: